Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia

References

• Centers for Disease Control and Prevention National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 Atlanta, GA Department of Health and Human Services, Centers for Disease Control and Prevention 2011
   Google Scholar
• American Diabetes Association Diabetes statistics Available from: http://www.diabetes.org/diabetes-basics/statistics/ Accessed November 6, 2013
   Google Scholar
• Boyle JP Thompson TJ Gregg EW Barker LE Williamson DF Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence Popul Health Metr 2010 8 29 20969750
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 1993 329 14 977 986 8366922
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Cryer PE Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes Diabetologia 2002 45 7 937 948 12136392
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
   PubMed Web of Science ®Google Scholar
• Abraira C Colwell JA Nuttall FQ Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes Diabetes Care 1995 18 8 1113 1123 7587846
   PubMed Web of Science ®Google Scholar
• Saudek CD Duckworth WC Giobbie-Hurder A Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group JAMA 1996 276 16 1322 1327 8861991
   PubMed Web of Science ®Google Scholar
• MacLeod KM Hepburn DA Frier BM Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients Diabet Med 1993 10 3 238 245 8485955
   PubMed Web of Science ®Google Scholar
• Henry RR Gumbiner B Ditzler T Wallace P Lyon R Glauber HS Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial Diabetes Care 1993 16 1 21 31 8422777
   PubMed Web of Science ®Google Scholar
• Bell DS Yumuk V Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin Endocr Pract 1997 3 5 281 283 15251781
   PubMedGoogle Scholar
• Hepburn DA Deary IJ Frier BM Patrick AW Quinn JD Fisher BM Symptoms of acute insulin-induced hypoglycemia in humans with and without IDDM. Factor-analysis approach Diabetes Care 1991 14 11 949 957 1797507
   PubMed Web of Science ®Google Scholar
• Landstedt-Hallin L Adamson U Lins PE Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes J Clin Endocrinol Metab 1999 84 9 3140 3145 10487677
   PubMed Web of Science ®Google Scholar
• McAulay V Frier BM Hypoglycemia Sinclair AJ Finucane P Diabetes in Old Age 2nd ed Chichester, UK John Wiley and Sons 2001 133 152
   Google Scholar
• Desouza C Salazar H Cheong B Murgo J Fonseca V Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring Diabetes Care 2003 26 5 1485 1489 12716809
   PubMed Web of Science ®Google Scholar
• Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group Diabetes Care 1988 11 7 567 573 2904881
   PubMed Web of Science ®Google Scholar
• Campbell IW Metformin and the sulphonylureas: the comparative risk Horm Metab Res Suppl 1985 15 105 111 3935560
   PubMedGoogle Scholar
• Kalra S Mukherjee JJ Venkataraman S Hypoglycemia: The neglected complication Indian J Endocrinol Metab 2013 17 5 819 834 24083163
   PubMedGoogle Scholar
• Hartling SG Faber OK Wegmann ML Wåhlin-Boll E Melander A Interaction of ethanol and glipizide in humans Diabetes Care 1987 10 6 683 686 3428047
   PubMed Web of Science ®Google Scholar
• Tattersall RB Frequency, causes and treatment of hypoglycemia Frier BM Fisher BM Hypoglycaemia in Clinical Diabetes Chichester, UK John Wiley and Sons 1999 55 88
   Google Scholar
• United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group Ann Intern Med 1998 128 3 165 175 9454524
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB American Diabetes Association European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 1 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Holstein A Hammer C Hahn M Kulamadayil NS Kovacs P Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients Expert Opin Drug Saf 2010 9 5 675 681 20553106
   PubMed Web of Science ®Google Scholar
• Feil DG Rajan M Soroka O Tseng CL Miller DR Pogach LM Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy J Am Geriatr Soc 2011 59 12 2263 2272 22150156
   PubMed Web of Science ®Google Scholar
• Shah N Mohammad A Afridi H Prevalence, risk factors and outcomes of hypoglycemia in elderly diabetic patients J Postgrad Med Inst 2013 26 3 272 276
   Google Scholar
• Hsia SH Insulin glargine compared to NPH among insulin-naïve, US inner city, ethnic minority type 2 diabetic patients Diabetes Res Clin Pract 2011 91 3 293 299 21146881
   PubMed Web of Science ®Google Scholar
• Pugh SK Doherty DA Magann EF Chauhan SP Hill JB Morrison JC Does hypoglycemia following a glucose challenge test identify a high risk pregnancy? Reprod Health 2009 6 10 19602284
   PubMedGoogle Scholar
• Kalra S Mukherjee JJ Venkataraman S Hypoglycemia: The neglected complication Indian J Endocrinol Metab 2013 17 5 819 834 24083163
   PubMedGoogle Scholar
• Edelman SV Henry RR Diagnosis and Management Off Type 2 Diabetes 4th ed Caddo Professional Communications 2001
   Google Scholar
• Precose® (acarbose) [package insert] Wayne, NJ Bayer Healthcare 2011
   Google Scholar
• Glyset® (miglitol) [package insert] New York, NY Pharmacia and Upjohn 2012
   Google Scholar
• Symlin® (pramlintide) [package insert] San Diego, CA Amylin 2008
   Google Scholar
• Glucophage® (metformin) [package insert] Princeton, NJ Bristol Myers Squibb 2009
   Google Scholar
• Onglyza® (saxaliptin) [package insert] Princeton, NJ Bristol Myers Squibb 2013
   Google Scholar
• Januvia® (sitagliptin) [package insert] Whitehouse Station, NJ Merck 2010
   Google Scholar
• Tradjenta® (linagliptin) [package insert] Ridgefield, CT Boehringer Ingelheim 2013
   Google Scholar
• Byetta® (exenatide) [package insert] San Diego, CA Amylin 2011
   Google Scholar
• Bydureon® (exenatide LAR) [package insert] San Diego, CA Amylin 2012
   Google Scholar
• Victoza® (liraglutide) [package insert] Plainsboro, NJ Novo Nordisk 2013
   Google Scholar
• Starlix® (nateglinide) [package insert] East Hanover, NJ Novartis 2013
   Google Scholar
• Nesina® (alogliptin) [package insert] Deerfield, IL Takeda 2013
   Google Scholar
• Prandin® (repaglinide) [package insert] Plainsboro, NJ Novo Nordisk 2011
   Google Scholar
• Diabeta® (acarbose) [package insert] Bridgewater, NJ Sanofi Aventis 2013
   Google Scholar
• Glucotrol® (glipizide) [package insert] New York, NY Pfizer 2013
   Google Scholar
• Amaryl® (glimepiride) [package insert] Bridgewater, NJ Sanofi Aventis 2009
   Google Scholar
• Actos® (pioglitazone) [package insert] Deerfield, IL Takeda 2013
   Google Scholar
• Avandia® (rosiglitazone) [package insert] Research Triangle Park, NC GlaxoSmithKline 2013
   Google Scholar
• Invokana® (canagliflozin) [package insert] Titusville, NC Janssen 2013
   Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists AACE comprehensive diabetes management algorithm 2013 Endocr Pract 2013 19 2 327 336 23598536
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Nagi DK Yudkin JS Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups Diabetes Care 1993 16 4 621 629 8462390
   PubMed Web of Science ®Google Scholar
• Grant PJ The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes Diabetes Care 1996 19 1 64 66 8720537
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Goodman AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group N Engl J Med 1995 333 9 541 549 7623902
   PubMed Web of Science ®Google Scholar
• Chan NN Brain HP Feher MD Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diabet Med 1999 16 4 273 281 10220200
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 17517853
   PubMed Web of Science ®Google Scholar
• Goldberg RB Kendall DM Deeg MA GLAI Study Investigators A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 2005 28 7 1547 1554 15983299
   PubMed Web of Science ®Google Scholar
• Loke YK Singh S Furberg CD Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis CMAJ 2009 180 1 32 39 19073651
   PubMed Web of Science ®Google Scholar
• Deacon CF Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review Diabetes Obes Metab 2011 13 1 7 18 21114598
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Sitagliptin 036 Study Group Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 8 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Van de Laar FA Lucassen PL Akkermans RP Alpha-glucosidate inhibitors for type 2 diabetes mellitus [review] Cochrane Database Syst Rev 2009 2 CD003639 15846673
   PubMed Web of Science ®Google Scholar
• Scheen AJ Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials Diabetes Metab 1998 24 4 311 320 9805641
   PubMed Web of Science ®Google Scholar
• Garber AJ Abrahamson MJ Barzilay JI American Association of Clinical Endocrinologists AACE comprehensive diabetes management algorithm 2013 Endocr Pract 2013 19 2 327 336 23598536
   PubMed Web of Science ®Google Scholar
• Little S Shaw J Home P Hypoglycemia rates with basal insulin analogs Diabetes Technol Ther 2011 13 Suppl 1 S53 S64 21668338
   PubMed Web of Science ®Google Scholar
• Stenlöf K Cefalu WT Kim KA Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin [Epub ahead of print.]
   Web of Science ®Google Scholar
• Varghese P Gleason V Sorokin R Senholzi C Jabbour S Gottlieb JE Hypoglycemia in hospitalized patients treated with antihyperglycemic agents J Hosp Med 2007 2 4 234 240 17702035
   PubMed Web of Science ®Google Scholar
• Gerich J Raskin P Jean-Louis L Purkayastha D Baron MA PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin Diabetes Care 2005 28 9 2093 2099 16123472
   PubMed Web of Science ®Google Scholar
• Modi P Diabetes beyond insulin: review of new drugs for treatment of diabetes mellitus Curr Drug Discov Technol 2007 4 1 39 47 17630927
   PubMedGoogle Scholar
• Ferner RE Neil HA Sulphonylureas and hypoglycaemia Br Med J (Clin Res Ed) 1988 296 6627 949 950
   Web of Science ®Google Scholar
• DeFronzo RA Pharmacologic therapy for type 2 diabetes mellitus Ann Intern Med 1999 131 4 281 303 10454950
   PubMed Web of Science ®Google Scholar
• Shorr RI Ray WA Daugherty JR Griffin MR Individual sulfonylureas and serious hypoglycemia in older people J Am Geriatr Soc 1996 44 7 751 755 8675920
   PubMed Web of Science ®Google Scholar
• Brodows RG Benefits and risks with glyburide and glipizide in elderly NIDDM patients Diabetes Care 1992 15 1 75 80 1737544
   PubMed Web of Science ®Google Scholar
• Peters A Incretin-based therapies: review of current clinical trial data Am J Med 2010 123 Suppl 3 S28 S37 20206729
   PubMed Web of Science ®Google Scholar
• Butler PC Chou J Carter WB Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans Diabetes 1990 39 6 752 756 2189768
   PubMed Web of Science ®Google Scholar
• Schmitz O Brock B Rungby J Amylin agonists: a novel approach in the treatment of diabetes Diabetes 2004 53 Suppl 3 S233 S238 15561917
   PubMed Web of Science ®Google Scholar
• Janka HU Plewe G Riddle MC Kliebe-Frisch C Schweitzer MA Yki-Järvinen H Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes Diabetes Care 2005 28 2 254 259 15677775
   PubMed Web of Science ®Google Scholar
• Goudswaard AN Furlong NJ Rutten GE Stolk RP Valk GD Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus Cochrane Database Syst Rev 2004 4 CD003418 15495054
   PubMedGoogle Scholar
• Siebenhofer A Plank J Berghold A Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus Cochrane Database Syst Rev 2006 2 CD003287 16625575
   PubMed Web of Science ®Google Scholar
• Home PD Lindholm A Riis A European Insulin Aspart Study Group Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial Diabet Med 2000 17 11 762 770 11131100
   PubMed Web of Science ®Google Scholar
• Bolen S Feldman L Vassy J Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 2007 147 6 386 399 17638715
   PubMed Web of Science ®Google Scholar
• Bennett WL Maruthur NM Singh S Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 2011 154 9 602 613 21403054
   PubMed Web of Science ®Google Scholar
• Ratner RE Want LL Fineman MS Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes Diabetes Technol Ther 2002 4 1 51 61 12017421
   PubMedGoogle Scholar
• Hollander PA Levy P Fineman MS Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial Diabetes Care 2003 26 3 784 790 12610038
   PubMed Web of Science ®Google Scholar
• Garber AJ Duncan TG Goodman AM Mills DJ Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial Am J Med 1997 103 6 491 497 9428832
   PubMed Web of Science ®Google Scholar
• Aronoff S Rosenblatt S Braithwaite S Egan JW Mathisen AL Schneider RL Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes Care 2000 23 11 1605 1611 11092281
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Wang JS Huang CN Hung YJ Acarbose/metformin fixed-dose combination study investigators Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes Diabetes Res Clin Pract 2013 102 1 16 24 23993469
   PubMed Web of Science ®Google Scholar
• Cryer PE Hypoglycemia Pathophysiology, Diagnosis and Treatment New York Oxford University Press 1997
   Google Scholar
• Noh RM Graveling AJ Frier BM Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review Expert Opin Pharmacother 2011 12 14 2161 2175 21668402
   PubMed Web of Science ®Google Scholar
• Bolli GB How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes Diabetes Care 1999 22 Suppl 2 B43 B52 10097899
   PubMed Web of Science ®Google Scholar
• Davis S Alonso MD Hypoglycemia as a barrier to glycemic control J Diabetes Complications 2004 18 1 60 68 15019602
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Ceriello A Gallo M Armentano V Perriello G Gentile S De Micheli A Associazione Medici Diabetologi Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach Diabetes Technol Ther 2012 14 4 373 378 22216963
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Eng J Med 2008 358 2545 2559
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar